Abstracts tagged "APRIL"

Abstract Number: 2797 • 2013 ACR/ARHP Annual Meeting
B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Ioannis Parodis¹, Agneta Zickert¹, Elisabet Svenungsson², Vivianne Malmström² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: B-lymphocytes have a pivotal role in the pathogenesis of Systemic Lupus Erythematosus (SLE). B-Lymphocyte Stimulator (BLyS) has an important role in the activation, differentiation…
Abstract Number: 2551 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial
David A. Isenberg¹, David Wofsy², Yong Li³, Daiana Licu⁴, Stephen D. Wax⁵, Caroline Gordon⁶ and Claudia Pena Rossi⁴, ¹Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ²Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ³EMD Serono, Rockland, MA, ⁴Merck Serono S.A., Geneva, Switzerland, ⁵Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that inhibits B cell stimulating factors BLyS and APRIL. We examined the pharmacodynamic (PD) effects of atacicept in patients…
Abstract Number: 1759 • 2012 ACR/ARHP Annual Meeting
Expression of Surface APRIL and Its Receptor, TACI, Is Upregulated On B Cells From Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients
Abby Jones Weldon¹, Sheri Hsu², Seyed K. Nazeri³, Saru Sachdeva², Jennifer Gonzalez⁴, Andrea D. Parra⁵, Abigail Benitez¹, Keith K. Colburn⁶, Ioana Moldovan⁷ and Kimberly J. Payne⁸, ¹Microbiology and Molecular Genetics, Loma Linda University, Loma Linda, CA, ²Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ³Rheumatology, Loma Lida University Medical Center, Loma Lida, CA, ⁴Center of Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁵Center for Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁶Dept Med - Rheum Sect, Loma Linda Univ Medical Center, Loma Linda, CA, ⁷Loma Linda Univ Medical Center, Loma Linda, CA, ⁸Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA
Background/Purpose: Autoimmune disease affects more than 23 million Americans. Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) are chronic, systemic B-cell mediated autoimmune diseases. During…
Abstract Number: 1756 • 2012 ACR/ARHP Annual Meeting
Peripheral Blood B Cell Subsets and BAFF/APRIL Receptor Expression, Together with Circulating BAFF and APRIL Levels, Are Disturbed in Rheumatoid Arthritis but Not in Ankylosing Spondylitis
Béatrice Gaugler¹, Caroline Laheurte², Ewa Bertolini³, Daniel Wendling⁴, Philippe Saas⁵, Eric Toussirot⁶ and CIC BT506⁷, ¹EFS Bourgogne Franche Comté, INSERM UMR1098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, ²Etablissement Français du Sang/ Université de Franche Comté / CBT506 / CHRU, INSERM UMR1098 / Plateforme Biomonitoring, Besançon, France, ³University Hospital, Rheumatology, Besançon, France, ⁴Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁵Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, ⁶Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ⁷Chru, Clinical Investigation Center Biotherapy, Besançon, France
Background/Purpose: B cells play a critical role in systemic autoimmune disease and especially rheumatoid arthritis (RA). BAFF and APRIL are involved in B cell activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].